Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Prostate Cancer

Free Subscription 22.12.2025 1 AJR Am J Roentgenol 1 BJU Int 1 BMC Cancer 2 BMC Urol 1 Br J Cancer 1 Clin Cancer Res 1 Eur Radiol 8 Eur Urol 1 Int J Radiat Oncol Biol Phys 1 J Magn Reson Imaging 1 Mod Pathol 2 PLoS One 6 Prostate 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. PONSIGLIONE A
   Closing the Gap: Standardizing MRI for Prostate Cancer Local Staging.
   AJR Am J Roentgenol. 2025 Dec 17. doi: 10.2214/AJR.25.34406.
   PubMed        
   
   

   
   BJU Int

2. BATOUCHE AO, Czeizler E, Lehto TP, Erickson A, et al
   Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.
   BJU Int. 2025 Dec 14. doi: 10.1111/bju.70109.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. OLIVA M, Boitano M, Carbone A, Briata IM, et al
   Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer. a real-world study with implications for cancer prevention/interception.
   BMC Cancer. 2025 Dec 18. doi: 10.1186/s12885-025-15396.
   PubMed         Abstract available
   
   

   
   BMC Urol

4. JIANG J, Wang K, Xie X, Mo X, et al
   Transperineal cognitive fusion MRI-targeted biopsy shows higher detection rates than systematic biopsy in prostate cancer: a prospective cohort study.
   BMC Urol. 2025 Dec 19. doi: 10.1186/s12894-025-02014.
   PubMed         Abstract available
   
   
5. YAN Y, Shuang S, Fan Z, Wei Z, et al
   Role of APOC1 and NOP16 in the diagnosis of prostate cancer.
   BMC Urol. 2025 Dec 17. doi: 10.1186/s12894-025-02017.
   PubMed         Abstract available
   
   

   
   Br J Cancer

6. LIN R, Un H, Kang Y, Lei J, et al
   Senescence-related gene signature predicts prostate cancer progression and identifies PCNA as a therapeutic target via multi-omics machine learning integration.
   Br J Cancer. 2025 Dec 18. doi: 10.1038/s41416-025-03309.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

7. KU AT, Shankavaram U, Trostel SY, Zhang H, et al
   Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-beta Activity Driving Tumor Recurrence.
   Clin Cancer Res. 2025;31:5211-5224.
   PubMed         Abstract available
   
   

   
   Eur Radiol

8. OZYORUK KB, Harmon SA, Yilmaz EC, Huang EP, et al
   Artificial intelligence-generated apparent diffusion coefficient (AI-ADC) maps for prostate gland assessment: a multi-reader study.
   Eur Radiol. 2026;36:288-295.
   PubMed         Abstract available
   
   

   
   Eur Urol

9. BACKHAUS P, Cazzamalli S, Oehler S, Buther F, et al
   Translational and First-in-Human Positron Emission Tomography Targeting Prostatic Acid Phosphatase in Prostate Cancer Using the Ligand [(68)Ga]Ga-OncoACP3-DOTA.
   Eur Urol. 2025 Dec 17:S0302-2838(25)04848-1. doi: 10.1016/j.eururo.2025.
   PubMed         Abstract available
   
   
10. JANI AB, Dhere VR, Goyal S, Schreibmann E, et al
    [(18)F]-Fluciclovine or [(68)Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial.
    Eur Urol. 2025 Dec 17:S0302-2838(25)04857-2. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    
11. MESSINA E, Borrelli A, Sciarra A, Laschena L, et al
    Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA).
    Eur Urol. 2025 Dec 17:S0302-2838(25)04847-X. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    
12. NGUYEN DD, Kulkarni GS, Guyatt GH
    Re: European Study of Prostate Cancer Screening - 23-Year Follow-up.
    Eur Urol. 2025 Dec 16:S0302-2838(25)04862-6. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    
13. MCKENZIE J, Azad AA
    Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 Trial.
    Eur Urol. 2025 Dec 16:S0302-2838(25)04861-4. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    
14. PEDRANI M, Gillessen S, Briers E, Blanchard P, et al
    Beyond Menopause: Ending the Inequality-Why Men with Prostate Cancer Still Lack Therapies for Hot Flushes.
    Eur Urol. 2025 Dec 13:S0302-2838(25)04856-0. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    
15. VICKERS AJ, Fine S
    Evaluating Tumor Quantification in Place of Proportions in Prostate Cancer: Principles of the ProQuant Group.
    Eur Urol. 2025 Dec 18:S0302-2838(25)04835-3. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    
16. CARLSSON SV, Krilaviciute A, Al-Monajjed R, Seibold P, et al
    Risk-adapted Prostate Cancer Screening Achieves Mammography-like Benefits: Evidence and Implications for Europe.
    Eur Urol. 2025 Dec 18:S0302-2838(25)04855-9. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

17. PERRIN J, Overdevest N, Tamborino G, Nonnekens J, et al
    Evaluating the Immune Response After Targeted Radionuclide Therapy: Toward a Correlation Between Absorbed Dose and Response.
    Int J Radiat Oncol Biol Phys. 2026;124:177-189.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

18. DENG S, Hu J, Wang H, Han X, et al
    Biparametric MRI-Based Habitat Analysis Integrated With Deep Learning for Predicting Clinically Significant Prostate Cancer in PI-RADS Category 3 Lesions.
    J Magn Reson Imaging. 2025 Dec 15. doi: 10.1002/jmri.70205.
    PubMed         Abstract available
    
    

    
    Mod Pathol

19. NATEGHI R, Zhou R, Saft M, Schnauss M, et al
    Artificial Intelligence (AI)-Driven Screening of Equivocal Prostate Immunohistochemistry (IHC) Cases: Development and Validation of a Screening and Cancer Detection Framework.
    Mod Pathol. 2025;38:100904.
    PubMed         Abstract available
    
    

    
    PLoS One

20. KOEHLER J, Lama D, Mendez M, Hsu WW, et al
    Phase II trial protocol of focal prostate ablation combined with androgen deprivation therapy for prostate cancer treatment.
    PLoS One. 2025;20:e0337828.
    PubMed         Abstract available
    
    
21. TEREK-DERSZNIAK M, Gasior-Perczak D, Biskup M, Skowronek T, et al
    Phenotypic stratification predicts the pace, but not the outcome, of continence recovery after radical prostatectomy.
    PLoS One. 2025;20:e0338900.
    PubMed         Abstract available
    
    

    
    Prostate

22. YU V, Treacy PJ, Thanigasalam R, Ahmadi N, et al
    Robotic-Assisted Radical Prostatectomy in the Elderly Patient-A Study of Functional, Surgical, and Oncological Outcomes in an Australian Cohort.
    Prostate. 2026;86:158-166.
    PubMed         Abstract available
    
    
23. YANG L, Wang X, Li Z, Huang F, et al
    Zonal-Specific Risk Stratification Integrating Magnetic Resonance Imaging and Prostate-Specific Antigen Density for Optimizing Prostate Biopsy Selection in Prostate-Specific Antigen 4-20 ng/mL Patients.
    Prostate. 2026;86:236-248.
    PubMed         Abstract available
    
    
24. KAUFMANN B, Choudhary M, Maheshwari A, Bhardwaj S, et al
    Diagnostic Value of Micro-Ultrasound in Identifying Local Recurrence After Radical Prostatectomy.
    Prostate. 2026;86:189-195.
    PubMed         Abstract available
    
    
25. TOKUNAGA T, Nishioka M, Kobayashi K, Hirata H, et al
    Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3-5 Lesions.
    Prostate. 2026;86:262-271.
    PubMed         Abstract available
    
    
26. OZAWA Y, Moschovas MC, Sandri M, Sharma R, et al
    Cell Cycle Progression Score Identifies Biopsy-Undetected Grade Group 5 Prostate Cancer.
    Prostate. 2025 Dec 17. doi: 10.1002/pros.70112.
    PubMed         Abstract available
    
    
27. MA H, Cao A, Hou H, Wu P, et al
    Diagnostic Value of Rapid On-Site Evaluation Combined With Prostate Biopsy in Prostate Cancer.
    Prostate. 2025 Dec 19. doi: 10.1002/pros.70113.
    PubMed         Abstract available
    
    

    
    Urology

28. DIAZ GM, Sivanesan N, Strachan S, Sohoni N, et al
    Sociodemographic Factors Associated with Tissue-Based Genomic Testing for Prostate Cancer.
    Urology. 2025 Dec 16:S0090-4295(25)01357-3. doi: 10.1016/j.urology.2025.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.